
Pentadecanoic acid (C15:0)
C15:0 capsules raise blood C15:0 levels. Two small 12-week trials found at most small changes in liver enzymes or LDL cholesterol, and the links with less diabetes and lower blood pressure come from observational studies that cannot show cause and effect.
Quick decision guide
May help most
Adults curious about the research who understand the evidence is early; there is no group for whom a benefit has been shown
Common dosing range
200 mg per day was the dose in the 12-week trial in young adults (two 100 mg capsules each morning)
When to expect effects
Blood levels rose within 12 weeks; no health effect has been confirmed
Watch out for
Only short, small trials exist, and much of the research is funded by the company that sells it; safety beyond 12 weeks, in pregnancy and in children is unknown
What is it
Pentadecanoic acid, usually written C15:0, is a saturated fat with 15 carbon atoms. It is called an odd-chain fatty acid because most fats in food have an even number of carbons. It occurs in small amounts in dairy fat and in some fish and plants, and blood levels of C15:0 are used in research as a marker of how much dairy fat people eat. It is now sold as a capsule supplement. Much of the research and promotion behind it comes from the company that sells it: in a 2020 laboratory paper that proposed C15:0 as a potential essential fatty acid, the lead scientist declared that she co-founded and works for Epitracker and Seraphina Therapeutics, which financed studies in that paper and hold licensing rights from the U.S. Navy to sell odd-chain fatty acids as health products. Most of the human evidence is observational (people with higher blood levels compared with people with lower levels); two small 12-week trials with added C15:0 have been published.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
blood C15:0 levels Limited Evidence | Blood C15:0 1.88 μg/mL higher than placebo after 12 weeks | Young adults with overweight or obesity (the only group studied with capsules) | 12 weeks |
liver enzymes and liver fat Limited Evidence | GGT 11 U/L lower than placebo; no clear extra effect on liver fat beyond diet | Adults with overweight or fatty liver, as studied | 12 weeks |
LDL cholesterol Limited Evidence | Extra LDL lowering beyond diet in one trial; size not stated in the abstract | Women with fatty liver who were also losing weight on a structured diet | 12 weeks |
type 2 diabetes risk (observational only) Mixed Evidence | About 20 to 32 percent lower diabetes rates with higher blood levels (association) | Not established | Not applicable (observational) |
blood pressure and heart disease (observational only) Mixed Evidence | About 1 to 1.5 mm Hg lower blood pressure per standard deviation (association); no link with heart disease | Not established | Not applicable (observational) |
inflammation, anemia and aging (cell and animal studies only) Mixed Evidence | Not measured in humans | Not established | Unknown |
blood C15:0 levels
- Effect
- Blood C15:0 1.88 μg/mL higher than placebo after 12 weeks
- Best fit
- Young adults with overweight or obesity (the only group studied with capsules)
- Time
- 12 weeks
liver enzymes and liver fat
- Effect
- GGT 11 U/L lower than placebo; no clear extra effect on liver fat beyond diet
- Best fit
- Adults with overweight or fatty liver, as studied
- Time
- 12 weeks
LDL cholesterol
- Effect
- Extra LDL lowering beyond diet in one trial; size not stated in the abstract
- Best fit
- Women with fatty liver who were also losing weight on a structured diet
- Time
- 12 weeks
type 2 diabetes risk (observational only)
- Effect
- About 20 to 32 percent lower diabetes rates with higher blood levels (association)
- Best fit
- Not established
- Time
- Not applicable (observational)
blood pressure and heart disease (observational only)
- Effect
- About 1 to 1.5 mm Hg lower blood pressure per standard deviation (association); no link with heart disease
- Best fit
- Not established
- Time
- Not applicable (observational)
inflammation, anemia and aging (cell and animal studies only)
- Effect
- Not measured in humans
- Best fit
- Not established
- Time
- Unknown
Evidence for 6 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
blood C15:0 levels
Biomarker supportIn a 12-week double-blind trial in 30 adults aged 18 to 25 with overweight or obesity (average age 20, average BMI 33.4), 20 took 200 mg of C15:0 a day and 10 took placebo. Blood C15:0 rose by 1.88 μg/mL more than with placebo. Half of the people taking C15:0 reached a level above 5 μg/mL, a threshold proposed in earlier research, including the company's own. The trial was partially supported by the NIH and also by Seraphina Therapeutics, including the C15:0 capsules and matching placebo; the authors declared no conflict with the company.
Bottom line: The capsules do raise blood C15:0; whether that helps health is unproven.
liver enzymes and liver fat
Biomarker supportIn the 12-week trial of 30 young adults, C15:0 lowered the liver enzyme GGT by 11 U/L more than placebo, but did not change ALT, AST or the other measured outcomes compared with placebo. Larger drops in ALT and AST were seen only in an exploratory comparison of people who reached higher blood levels. In the TANGO trial, 88 Chinese women with fatty liver followed an Asian-adapted Mediterranean-style diet with or without added C15:0, or their usual diet, for 12 weeks. Liver fat fell by 33 percent with diet plus C15:0, 30 percent with diet alone and 10 percent with usual diet; the abstract reports an added effect of C15:0 for LDL cholesterol and one gut bacterium, while the drop in liver fat was similar with diet alone and went along with weight loss. TANGO was funded by Singapore's Agency for Science, Technology and Research (A*STAR), its trial registry lists the food company Wilmar International as a collaborator, and its authors declared no conflicts of interest.
Bottom line: A small change in one liver enzyme; diet did the heavy lifting for liver fat.
Evidence is mixed
ALT and AST did not change compared with placebo in the capsule trial, and in TANGO the liver fat drop was similar with or without C15:0.
LDL cholesterol
Biomarker supportIn the TANGO trial (88 Chinese women with fatty liver, 12 weeks), adding C15:0 to an Asian-adapted Mediterranean-style diet lowered LDL cholesterol further than the diet alone. The abstract does not give the size of the extra drop. In the separate 12-week capsule trial in 30 young adults, cholesterol did not change compared with placebo.
Bottom line: One trial suggests a small extra LDL drop; it has not been confirmed.
Evidence is mixed
The capsule trial in young adults found no cholesterol change compared with placebo.
type 2 diabetes risk (observational only)
Biomarker supportA pooled analysis of 16 cohort studies (63,682 adults followed for about 9 years) found that people with blood C15:0 at the high end of their cohort's range had a 20 percent lower rate of type 2 diabetes than those at the low end (hazard ratio 0.80). A 2026 review of 27 articles on prospective cohort studies found a similar link (summary relative risk 0.68 for higher C15:0 in blood phospholipids and red blood cells, moderate certainty). These studies measured blood levels that mostly reflect dairy fat intake, not supplement use. They cannot show that C15:0 prevents diabetes, and no trial has tested whether a C15:0 supplement lowers diabetes risk.
Bottom line: An interesting association, not proof that a C15:0 pill prevents diabetes.
blood pressure and heart disease (observational only)
Biomarker supportIn 3,196 adults from the US CARDIA study (average age 45), each standard-deviation increase in blood C15:0 went with 1.47 mm Hg lower systolic and 1.13 mm Hg lower diastolic blood pressure and a 14 percent lower rate of new high blood pressure over about 10 years; these links were repeated in 3,889 White adults from the ARIC study (average age 54). Blood C15:0 was not linked to new heart disease in either group or to heart function. A genetic analysis designed to test cause and effect found no evidence that C15:0 lowers blood pressure, and the authors concluded the evidence is not consistent with a causal heart benefit. The authors declared no commercial conflicts and reported funding from the US National Heart, Lung, and Blood Institute.
Bottom line: Small blood pressure links, no heart disease link, and no sign of cause and effect.
inflammation, anemia and aging (cell and animal studies only)
Mechanism onlyIn cell and animal studies, C15:0 lowered markers of inflammation, anemia, high blood fats and scarring, and the authors proposed it as a potential essential fatty acid. The paper declares that studies in it were financed by Epitracker and Seraphina Therapeutics, companies co-founded by the lead author that hold exclusive licensing rights to sell odd-chain fatty acids as health products. A 2024 review by the same scientist, who declares that she is employed by both companies, proposed a "Cellular Stability Hypothesis" and a C15:0 deficiency syndrome. These effects and ideas have not been shown in people; the claims about aging and longevity rest on laboratory work.
Bottom line: Laboratory findings from company-funded work, not human benefits.
How it works
How to take it
What to track
Bottom line: A dose has been tested for 12 weeks; a health benefit has not been shown.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Long-term safety is unknown: the published supplement trials lasted only 12 weeks and included few people
Who should avoid it
- Pregnant or breastfeeding women, since there are no human studies; in pregnant mice, a diet with 1 percent C15:0 caused mild glucose intolerance
- Children and teenagers, who have not been studied (the capsule trial enrolled ages 18 to 25)
Pregnancy & breastfeeding
C15:0 supplements have not been studied in pregnancy or breastfeeding. In one mouse study, a diet containing 1 percent C15:0 during pregnancy caused mild insulin resistance in the mothers, though it did not affect embryo development. Talk with your doctor before using it while pregnant or breastfeeding.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is C15:0 really an essential fatty acid?⌄
That idea was proposed by scientists linked to the companies that sells C15:0, based mainly on cell and animal studies. Essential means the body cannot make it and needs it from food to avoid a deficiency disease. No human trial has shown a deficiency disease that C15:0 supplements prevent or treat.
Who funded the research?⌄
The 2020 laboratory and animal paper that proposed C15:0 as a potential essential fatty acid declares that studies in it were financed by Epitracker and Seraphina Therapeutics, companies co-founded by the lead author. The 12-week capsule trial in young adults was partially supported by the NIH and by Seraphina Therapeutics, which supplied the capsules and placebo. The TANGO diet trial was funded by a Singapore government research agency (its registry lists the food company Wilmar International as a collaborator), and the 2026 CARDIA and ARIC blood pressure study reported NIH funding; the authors of both declared no conflicts of interest.
Is it better to eat dairy fat or take a C15:0 capsule?⌄
Neither has been proven to prevent disease. The links between higher blood C15:0 and less diabetes come from people whose levels mostly reflect dairy fat in their diet, so those findings say nothing direct about capsules. A 2026 genetic study found no evidence that C15:0 itself lowers blood pressure.
Can I take C15:0 with my medicines or other supplements?⌄
No interaction studies have been published for C15:0 supplements. Because the evidence is so limited, ask your doctor or pharmacist to look at your own list before you start, especially if you take medicines for cholesterol, diabetes or liver disease.
Is C15:0 safe?⌄
In a 12-week trial of 200 mg a day in 30 young adults, no significant side effects occurred. Nothing is known about longer use, use in older adults with health problems, pregnancy or children.
References by claim
blood C15:0 levels
Robinson et al., 2024 · PMC (2024) link
liver enzymes and liver fat
Chooi et al., 2024 · PubMed (2024) link
type 2 diabetes risk (observational only)
blood pressure and heart disease (observational only)
Steffen et al., 2026 · PMC (2026) link
inflammation, anemia and aging (cell and animal studies only)
Safety
Wang et al., 2024 · PubMed (2024) link
Track Pentadecanoic acid (C15:0) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments. Talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.
